Business
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital Management, HBM Healthcare Investments and SymBiosisProceeds expected to support the advancement of CX11, an oral small molecule GLP-1 receptor agonist (RA), across ongoing U.S. and planned global Phase 2 trials, and to advance additional cardiometabolic programs BERKELEY HEIGHTS, N.J., Jan. 22, 2026 (GLOBE
About this update from Hbm Healthcare Investments Ag Temp
[{"type":"image","alt":"Corxel Pharmaceuticals","displaySize":"","headline":null,"caption":"Corxel Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/34fc7d3d3f1d0af72a200d4aca1329c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RnOKGxK1ex8vOZKCGNoGOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/34fc7d3d3f1d0af72a200d4aca1329c7","width":300,"height":103}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital Management, HBM Healthcare Investments and SymBiosis","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"Proceeds expected to support the advancement of CX11, an oral small molecule GLP-1 receptor agonist (RA), across ongoing U.S. and planned global Phase 2 trials, and to advance additional cardiometabolic programs","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":455,"olType":false},{"type":"text","content":"BERKELEY HEIGHTS, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the successful completion of its Series D1 financing, raising up to $287 million in capital. Proceeds from the round are expected to support the advancement of CX11, a differentiated oral small molecule GLP-1 RA for obese and overweight patients currently being evaluated in a Phase 2 trial conducted by CORXEL in the United States and a Phase 3 trial conducted by Vincentage in China, and other cardiometabolic programs, including for acute ischemic stroke and hypertension.","length":746,"tagName":"p"},{"type":"text","content":"The financing included participation from new investors including SR One, TCGX, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital, and certain other investors. Existing investors, RTW Investments and Hengdian Group Capital also participated, underscoring continued conviction in CX11’s differe...